Traws Pharma Inc (TRAW)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.86M
Last updated: Nov 17, 2026 at 11:03 AM ET
Traws Pharma Inc (TRAW) Earnings: Report Dates and Results
Traws Pharma (TRAW) is expected to report earnings on Apr 13, 2027. In the quarter ended Jun 30, 2026, Traws Pharma reported EPS of -$0.16, above the -$0.22 estimate. It beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
TRAW has an expected report date of Apr 13, 2027.
TRAW Earnings Call
The latest TRAW earnings call transcript on file is labeled 2025Q4.
Read the 2025Q4 transcriptEarnings History
Of the 37 quarters below that had an estimate, TRAW beat 25, missed 10 and matched 2. The widest gap in the table came in the quarter ended Mar 31, 2025, when EPS landed 888.68% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$0.16 | -$0.22 | N/A | +27.27% | Beat | N/A | 1 | 1 up, 0 down | Aug 13, 2026 | N/A |
| Mar 31, 2026 | -$0.52 | -$0.56 | -$0.56 - -$0.56 | +7.14% | Beat | -124.9% | 1 | 1 up, 0 down | Apr 15, 2026 | N/A |
| Dec 31, 2025 | -$0.55 | -$0.54 | -$0.54 - -$0.54 | -2.67% | Miss | -102.1% | 1 | 0 up, 0 down | Dec 31, 2025 | $2.62M |
| Sep 30, 2025 | -$0.34 | -$9.16 | N/A | +96.29% | Beat | N/A | N/A | N/A | Nov 13, 2025 | N/A |
| Jun 30, 2025 | -$0.16 | -$8.75 | N/A | +98.17% | Beat | N/A | N/A | N/A | Aug 14, 2025 | $2.73M |
| Mar 31, 2025 | $2.09 | -$0.27 | N/A | +888.68% | Beat | N/A | N/A | N/A | May 15, 2025 | $57000 |
| Dec 31, 2024 | $26.60 | -$0.25 | N/A | N/A | N/A | N/A | N/A | 0 up, 0 down | Mar 31, 2025 | $57000 |
| Sep 30, 2024 | -$8.81 | -$6.25 | N/A | -40.96% | Miss | N/A | N/A | N/A | Nov 14, 2024 | $57000 |
| Jun 30, 2024 | -$121.75 | -$6.25 | N/A | N/A | N/A | N/A | N/A | 0 up, 0 down | Aug 15, 2024 | $57000 |
| Mar 31, 2024 | -$5.00 | -$6.33 | N/A | +21.01% | Beat | N/A | N/A | 0 up, 0 down | Apr 1, 2024 | $56000 |
| Dec 31, 2023 | -$0.19 | -$0.25 | N/A | +24.00% | Beat | N/A | N/A | N/A | Mar 14, 2024 | $56000 |
| Sep 30, 2023 | -$5.75 | -$7.25 | N/A | +20.69% | Beat | N/A | N/A | N/A | Nov 14, 2023 | $57000 |
| Jun 30, 2023 | -$5.00 | -$7.81 | N/A | +35.98% | Beat | N/A | N/A | N/A | Aug 10, 2023 | $57000 |
| Mar 31, 2023 | -$7.00 | -$7.44 | N/A | +5.91% | Beat | N/A | N/A | N/A | May 15, 2023 | $56000 |
| Dec 31, 2022 | -$0.26 | -$0.26 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 16, 2023 | $56000 |
| Sep 30, 2022 | -$6.50 | -$5.31 | N/A | -22.41% | Miss | N/A | N/A | N/A | Nov 14, 2022 | $57000 |
| Jun 30, 2022 | -$4.75 | -$4.94 | N/A | +3.85% | Beat | N/A | N/A | N/A | Aug 11, 2022 | $57000 |
| Mar 31, 2022 | -$5.00 | -$4.69 | N/A | -6.61% | Miss | N/A | N/A | N/A | May 11, 2022 | $56000 |
| Dec 31, 2021 | -$0.17 | -$0.17 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 17, 2022 | $56000 |
| Sep 30, 2021 | -$5.50 | -$8.17 | N/A | +32.68% | Beat | N/A | N/A | N/A | Nov 11, 2021 | $57000 |
| Jun 30, 2021 | -$6.75 | -$7.12 | N/A | +5.20% | Beat | N/A | N/A | N/A | Aug 12, 2021 | $57000 |
| Mar 31, 2021 | -$0.30 | -$0.45 | N/A | +33.33% | Beat | N/A | N/A | N/A | May 17, 2021 | $56000 |
| Dec 31, 2020 | -$11.25 | -$13.12 | N/A | +14.25% | Beat | -1078.3% | N/A | N/A | Mar 11, 2021 | $57000 |
| Sep 30, 2020 | -$11.25 | -$12.50 | N/A | +10.00% | Beat | N/A | N/A | N/A | Nov 12, 2020 | $66000 |
| Jun 30, 2020 | -$15.00 | -$11.25 | N/A | -33.33% | Miss | N/A | N/A | N/A | Aug 12, 2020 | $56000 |
| Mar 31, 2020 | -$11.25 | -$20.62 | N/A | +45.44% | Beat | N/A | N/A | N/A | May 14, 2020 | $52000 |
| Dec 31, 2019 | $1.15 | -$0.07 | N/A | N/A | N/A | N/A | N/A | N/A | Mar 24, 2020 | $30000 |
| Sep 30, 2019 | -$281.25 | -$255.00 | N/A | -10.29% | Miss | N/A | N/A | N/A | Nov 12, 2019 | $63000 |
| Jun 30, 2019 | -$225.00 | -$330.00 | N/A | +31.82% | Beat | N/A | N/A | N/A | Aug 14, 2019 | $2.02M |
| Mar 31, 2019 | -$483.75 | -$388.12 | N/A | -24.64% | Miss | N/A | N/A | N/A | May 14, 2019 | $68000 |
| Dec 31, 2018 | -$0.98 | -$0.97 | N/A | -1.03% | Miss | N/A | N/A | N/A | Mar 26, 2019 | $59000 |
| Sep 30, 2018 | -$352.50 | -$435.00 | N/A | +18.97% | Beat | N/A | N/A | N/A | Nov 13, 2018 | $120000 |
| Jun 30, 2018 | -$393.75 | -$431.25 | N/A | +8.70% | Beat | N/A | N/A | N/A | Aug 14, 2018 | $485000 |
| Mar 31, 2018 | -$5.10 | -$5.85 | N/A | +12.78% | Beat | N/A | N/A | N/A | May 15, 2018 | $564000 |
| Dec 31, 2017 | -$3,318.75 | -$3,867.19 | N/A | +14.18% | Beat | N/A | N/A | N/A | Mar 8, 2018 | $143000 |
| Sep 30, 2017 | -$3,993.75 | -$3,895.31 | N/A | -2.53% | Miss | N/A | N/A | N/A | Nov 9, 2017 | $110000 |
| Jun 30, 2017 | -$1,631.25 | -$4,068.75 | N/A | +59.91% | Beat | N/A | N/A | N/A | Aug 14, 2017 | $324000 |
| Mar 31, 2017 | -$6,918.75 | -$5,400.00 | N/A | -28.13% | Miss | N/A | N/A | N/A | May 15, 2017 | $210000 |
| Dec 31, 2016 | -$0.54 | -$15.00 | N/A | +96.40% | Beat | -400.0% | N/A | N/A | Mar 27, 2017 | $173000 |
| Sep 30, 2016 | -$4,443.75 | -$4,612.50 | N/A | +3.66% | Beat | N/A | N/A | N/A | Nov 14, 2016 | $1.65M |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $1.04, a profit after a loss of $108.96 per share the year before. It was -$30,975.74 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $1.04 | N/A |
| Dec 31, 2024 | -$108.96 | N/A |
| Dec 31, 2023 | -$17.94 | N/A |
| Dec 31, 2022 | -$16.51 | N/A |
| Dec 31, 2021 | -$12.72 | N/A |
| Dec 31, 2020 | -$48.75 | N/A |
| Dec 31, 2019 | -$988.85 | N/A |
| Dec 31, 2018 | -$752.33 | N/A |
| Dec 31, 2017 | -$15,862.50 | N/A |
| Dec 31, 2016 | -$30,975.74 | N/A |
Earnings Calls
The 2 most recent earnings calls are listed below; the latest, 2025Q4 for the period ended Dec 31, 2025, runs about 2,500 words across 5 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2025Q4 | Dec 31, 2025 | 2,502 | 5 | |
| 2025Q2 | Jun 30, 2025 | 2,698 | 6 |
2025Q4 Earnings Call
Opening remarks
John Fraunces Host / Moderator, LifeSci Advisors Thank you, operator, and welcome, everyone, to Traws Pharma's Full Year 2025 Financial Results and Business Update Conference Call. This afternoon, Traws issued a press release reporting its 2025 financial results and provided a business update. If you have not yet seen this press release, it is available in the Investor Relations section of the company's website. Following my introduction, we will hear from Traws's Chief Executive Officer, Dr. Iain Dukes; and Chief Financial Officer, Charles Parker. Before we begin, I would like to remind everyone that statements made during this conference call will include forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties that can cause actual results to differ materially. Forward-looking statements speak only as of the date they are made as the underlying facts and circumstances may change. Except as required by law, Traws disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances. For more information on forward-looking statements, please review the disclaimer in this morning's press release and the risk factors in the company's SEC filings. With that, I will now turn the call over to Traws's CEO, Dr. Iain Dukes.
Iain Dukes Chief Executive Officer (CEO) Thanks, John, and thanks to everyone for joining us today. Over the last year, Traws has made substantial progress towards our objective of bringing our differentiated next-generation antiviral candidate for influenza to patients. This morning, Traws announced a private financing of $60 million. The private financing was supported by new and existing health care-focused investors. The capital from this financing positions Traws to advance the flu program through a human challenge study this summer while providing access to additional capital as we achieve further key milestones. Influenza is estimated to be a multibillion-dollar opportunity spanning prophylactic and therapeutic applications, including strategic government stockpiling and pandemic preparedness incentives. The human challenge study trial focused on flu prevention is an important step towards establishing the potential for tivoxavir marboxil as a potential best-in-class prophylactic agent for flu prevention. We intend to initiate the study this summer once we have approval received from the Medicines and Healthcare products Regulatory Agency, or MHRA, in the U.K. During today's call, we will provide an overview of development of our lead candidate, tivoxavir marboxil or tivoxavir for short, for influenza. Tivoxavir marboxil is an exciting next-generation investigational influenza antiviral that targets the highly conserved cap-dependent endonuclease. We believe tivoxavir is well positioned to become a best-in-class once-monthly oral prophylactic agent with additional potential for pandemic flu, including H5N1 bird flu. We will prioritize development of tivoxavir as a once-monthly prophylactic agent for influenza prevention.
Frequently Asked Questions About TRAW
When is Traws Pharma's next earnings date?
Traws Pharma's next earnings report is expected for Apr 13, 2027.
Did TRAW beat earnings estimates last quarter?
Yes. Traws Pharma reported EPS of -$0.16 for the quarter ended Jun 30, 2026, above the -$0.22 estimate, a 27.27% surprise.
What EPS do analysts expect from TRAW next quarter?
The consensus EPS estimate for Traws Pharma for the quarter ending Dec 31, 2026 is -$0.24 from 4 analysts, with estimates from -$0.28 to -$0.20.
How often does TRAW beat earnings estimates?
Traws Pharma beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate, with an average surprise of +136.87%.
TRAW pages: Overview, Earnings, Forecast, Financials, Competitors